ライフサイエンスコーパス: sphinganine

1 evation of C16-ceramide, and/or elevation of sphinganine.

2 lol, and the sphingoid bases sphingosine and sphinganine.

3 species is conserved up to the formation of sphinganine.

4 t was inhibited by preincubating clusters in sphinganine.

5 increase cellular levels of sphingosine and sphinganine.

6 the 2-amino-1,3-diol polar head of D-erythro-sphinganine.

7 ectively reduced to either erythro- or threo-sphinganines.

8 Exposure to either sphingosine or sphinganine (0.001 10 microM) for 6 h promoted apoptotic

9 Similar to SPP, sphinganine 1-phosphate (dihydro-SPP), which also binds

10 SPP and sphinganine 1-phosphate bind to these receptors, whereas

11 inds SPP with remarkable specificity as only sphinganine-1-phosphate displaced radiolabeled SPP, whil

12 In contrast to SPP, sphinganine-1-phosphate, which binds to and signals thro

13 Conversely, sphinganine-1-phosphate, which binds to and signals via

14 specific for SPP, as only unlabeled SPP and sphinganine-1-phosphate, which lacks the trans double bo

15 Partially protected sphinganines 11 are also readily accessible in five step

16 c acid, caused sequential formation of [(3)H]sphinganine (220% over control) and [(3)H]ceramide (160%

17 A total synthesis of D-erythro-sphinganine [(2S,3R)-2-aminooctadecane-1,3-diol] startin

18 te hydrogen-bonding interactions between the sphinganine 3-OH with Asp-80.

19 (D-e-deh-Sph, IC50 0.25 mol %), (2S)-3-keto-sphinganine (3-keto-dh-Sph, IC50 0.34 mol %), (2S) 3-ket

20 Sphinganine, a positively charged sphingoid base, inhibi

21 A fluorescent analog of sphinganine accumulated in mitochondria.

22 The sphinganine analog mycotoxin, AAL-toxin, induces a death

23 i (AAL) toxins are members of a new class of sphinganine analog mycotoxins that occur widely in the f

24 e used to modulate the relative synthesis of sphinganine and 1-deoxySa.

25 s system was used to elevate sphingosine and sphinganine and determine if PKC was affected.

26 Whereas increases in sphinganine and dihydroceramide are responses to provisi

27 vator of PKC, and this effect was blocked by sphinganine and PKC(19-36), inhibitors of PKC in bag cel

28 Decreases in sphinganine and SM concentrations were also observed in

29 of the protein kinase C inhibitor D-erythro-sphinganine and the antitumor agent (+)-spisulosine, whe

30 Particularly, sphingosine, sphinganine, and C24Cer appear as promising novel biomar

31 Sphingosine, sphinganine, and other long-chain (sphingoid) bases are

32 bin activation was inhibited by sphingosine, sphinganine, and stearylamine in the presence but not in

33 This is significant because sphinganines are more easily accessed than phytosphingos

34 e, incorporation of 2-hydroxyoleic acid to a sphinganine base was also confirmed by MS/MS.

35 ow direct study of cellular sphingosine- and sphinganine-based ceramide levels, we developed a mass s

36 ariations of serum SLs, with sphingosine and sphinganine being, both in univariate (P<0.05) as well a

37 Sphingosine and sphinganine, but not ceramide or sphingosine-1-phosphate

38 Elevation of endogenous sphinganine by a second method (addition of fumonisin B1

39 ng; therefore, elevations in sphingosine and sphinganine can both affect PKC.

40 Sphinganines can be synthesized in just three steps from

41 Sphinganine caused an increase in the cooperativity of c

42 ases (including C2 ceramide, sphingosine, or sphinganine) caused the accumulation of cyt c in the cyt

43 rt-chain alpha-GalCer ligand PBS-25, but its sphinganine chain is more deeply inserted into the F' po

44 We have prepared the direct sphinganine-containing analogues of KRN7000 and OCH, 1 a

45 It was less potently inhibited by D-erythro-sphinganine (D-e-dh-Sph, IC50 0.20 mol %), D-erythro-deh

46 Fumonisin B1, the N-acyl-sphinganine dehydrogenase (e.g., ceramide synthase) inhi

47 ion of sphingomyelin (SM) precursors such as sphinganine, dihydroceramide, and ceramide; (b) inhibite

48 C16-ceramide, sphingosine, and sphinganine directly inhibited complex IV activity in is

49 On the other hand, sphinganine had little effect on the cooperativity of ph

50 or sphingomyelin are not substrates, whereas sphinganine has a limited capacity to accept the acetate

51 Thus, sphingosine and sphinganine increased both the potency and efficacy of c

52 We suggest that C16-ceramide and/or sphinganine induce ROS formation through the modulation

53 eat-induced increase in incorporation of [3H]sphinganine into ceramide as well as the heat-induced in

54 amides (Cers) with consecutive elevations in sphinganine levels has been shown to cause a severe hepa

55 e liver, including elevated C16-ceramide and sphinganine levels in liver and in isolated mitochondria

56 and phosphatidylethanolamine) and cationic (sphinganine) lipids, nucleotides (ATP and CTP), N-ethylm

57 in Western diet for 12 weeks lowered SM and sphinganine plasma levels.

58 50) = 2.4 and 1.4 microm for sphingosine and sphinganine, respectively) as well as in whole plasma cl

59 es are N-acyl derivatives of sphingosine and sphinganine, respectively, which are the major sphingoid

60 and [(3)H]ceramide (160% over control), with sphinganine returning to baseline at 4 h, and ceramide c

61 its corresponding dihydro-saturated species sphinganine (Sa), are present in cell samples in low abu

62 Inhibition of CerS by FB(1) increases sphinganine (Sa), Sa 1-phosphate, and a previously unide

63 o significantly reduced urinary excretion of sphinganine (Sa), sphingosine (So), and Sa/So ratio, but

64 of FB1, whereas the bioactive intermediates, sphinganine, sphingosine, and ceramide, were without eff

65 nd chain length of the N-acyl-spingosine or -sphinganine substrate.

66 st versatile templates described to date for sphinganine synthesis.

67 esemble the sphingoid bases, sphingosine and sphinganine, that are reported to play critical roles in

68 ion in response to 4-HPR treatment, although sphinganine was still generated when 4-HPR and FB(1) wer

69 e versatility of the method, spisulosine and sphinganine were synthesized in two steps from the appro